News | August 26, 2025
CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
Subscribe To Our Newsletter & Stay Updated
